Back

Protocol for using an ELISA assay to detect total α-synuclein levels in Drosophila melanogaster lines expressing human α-synuclein point mutations

Sciortino, M.; Velazquez, R.; Tillmon, H.; Banerjee, S.

2026-01-07 neuroscience
10.64898/2026.01.07.698009 bioRxiv
Show abstract

In Parkinsons disease (PD), aggregation of alpha-synuclein (-syn) contributes to neuronal dysfunction and death, particularly in dopaminergic neurons, driving disease progression. Several pathogenic point mutations have been identified in human -syn such as A30P, E46K, H50Q, G51D, A53T and A53E that have been associated with PD. In this study, a sandwich ELISA assay was developed to quantify total -syn levels in various Drosophila melanogaster genotypes expressing A30P, E46K, G51D and A53T. Using this approach, we compared -syn levels across wild-type (WT) and mutant forms of the protein. The E46K and A53T mutations exhibited higher total -syn concentrations compared to WT and the G51D mutation. In addition to characterizing mutation-dependent differences in -syn levels, this assay was applied to evaluate small-molecule modulators that inhibit -syn aggregation. These findings demonstrate that the ELISA-based approach provides a useful platform for quantifying -syn and assessing potential therapeutic compounds targeting syn pathology.

Published in STAR Protocols (predicted rank #1) · training set

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.